Plasminogen activator inhibitor-1 and adiponectin are associated with metabolic syndrome components
American Journal of Hypertension Sep 21, 2021
Vecchiola A, García K, González-Gómez LM, et al. - In a general population, PAI-1 and adiponectin had the most robust relationships with metabolic syndrome (MetS) components, showing that poor adipose tissue performance is a major contributor to these metabolic anomalies.
It was a cross-sectional study.
According to Harmonizing ATP III, 202 participants were categorized into MetS and No-MetS.
MetS patients had higher amounts of pro-inflammatory molecules but significantly lower levels of adiponectin than No-MetS individuals.
Among the adipocytokines investigated, PAI-1 and adiponectin had the strongest correlations with the majority of MetS components.
PAI-1 was found to be linked with MetS, whereas adiponectin was found to be inversely associated with MetS.
In a multivariate analysis, the link between PAI-1 and adiponectin with MetS remained significant after adjusting for gender, age, BMI, and 24-hour urine sodium excretion.
Multivariate analyses validated a model in which PAI-1, hsCRP, and MMP2 could predict systolic blood pressure; PAI-1 could predict diastolic blood pressure and glucose; PAI-1 and hsCRP could predict waist circumference.
According to ROC curve analysis, a PAI-1 concentration had the highest sensitivity and specificity for distinguishing people with MetS.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries